A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma.

Hainsworth, John D; Infante, Jeffrey R; Spigel, David R; Arrowsmith, Edward R; Boccia, Ralph V; Burris, Howard A

Hainsworth, John D; Infante, Jeffrey R; Spigel, David R; Arrowsmith, Edward R; Boccia, Ralph V; Burris, Howard A.

Affiliation

Hainsworth JD; Sarah Cannon Research Institute, Nashville, TN 37203, USA. jhainsworth@tnonc.com

Cancer Invest ; 29(7): 451-5, 2011 Aug.

Article in En | MEDLINE | ID: mdl-21696296

Subject(s)

Carcinoma, Renal Cell/drug therapy; Histone Deacetylase Inhibitors/therapeutic use; Hydroxamic Acids/therapeutic use; Kidney Neoplasms/drug therapy; Aged; Carcinoma, Renal Cell/mortality; Female; Humans; Hydroxamic Acids/adverse effects; Indoles; Kidney Neoplasms/mortality; Male; Middle Aged; Neoplasm Metastasis; Panobinostat

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Histone Deacetylase Inhibitors / Hydroxamic Acids / Kidney Neoplasms Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Invest Year: 2011 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google